# Stablix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/stablix

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.stablix.com
- Total disclosed funding: $63M
- Latest round: Series A (Jun 3, 2021)
- Investors on record: 5

## About

Based in New York, US, and established in 2021, Stablix, Inc. is a biotechnology research company working on targeted protein stabilization (TPS) to provide transformative medications for patients with unmet medical needs. The company was founded by Kevin Sprott (COO), Brian Bowman (SVP Biology), Henry Colecraft (Chair of SAB), and Scott Kanner (Associate Director, Platform Sciences) with a USD 63 million Series A funding (Jun 2021) led by founding investor Versant Ventures with New Enterprise Associates, Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. As of July 2022, Stablix is being led by its CEO, Tony Kingsley.

The company’s platform RESTORED™, which originated in a Columbia University laboratory, can remove the ubiquitin tags from specific proteins, and stabilize or drive an increase in target protein levels and activity. This is done by generating heterobifunctional small molecules that recruit deubiquitinase enzymes, or DUBs. The company’s medicines can be used for the treatment of oncology, immune-oncology, immunology, and rare diseases.

Stablix is planning to use the funding in building its platform and the advancement of its protein stabilizers products.

## Funding rounds

- Series A, Jun 3, 2021, $63M — New Enterprise Associates, Versant Ventures, Alexandria Venture Investments, Cormorant Asset Management, Euclidean Capital

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A
- Euclidean Capital — Series A